MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Agios Pharmaceuticals Inc

Closed

SectorHealthcare

28.43 3.8

Overview

Share price change

24h

Current

Min

26.51

Max

28.59

Key metrics

By Trading Economics

Income

-1B

-97M

Sales

1.7M

11M

P/E

Sector Avg

2.517

63.778

EPS

-1.74

Profit margin

-899.562

Employees

486

EBITDA

-21M

-124M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+105% upside

Dividends

By Dow Jones

Next Earnings

1 maj 2025

Market Stats

By TradingEconomics

Market Cap

-226M

1.7B

Previous open

24.63

Previous close

28.43

News Sentiment

By Acuity

50%

50%

180 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Agios Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 wrz 2024, 14:20 UTC

Acquisitions, Mergers, Takeovers

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

Peer Comparison

Price change

Agios Pharmaceuticals Inc Forecast

Price Target

By TipRanks

105% upside

12 Months Forecast

Average 56.17 USD  105%

High 74 USD

Low 43 USD

Based on 7 Wall Street analysts offering 12 month price targets forAgios Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

5

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

N/A / 30.81Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

180 / 386 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.